Loading...
Docoh

Champions Oncology (CSBR)

Champions Oncology is a data-driven research organization that leverages an oncology research center of excellence to develop transformative technology and accelerate oncology research and development. This technology ranges from computational-based discovery platforms, unique oncology software solutions, and innovative and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms.

Company profile

Ticker
CSBR
Exchange
CEO
Ronnie Morris
Employees
Incorporated
Location
Fiscal year end
Former names
CHAMPIONS BIOTECHNOLOGY, INC., CHAMPIONS SPORTS INC
SEC CIK
IRS number
521401755

CSBR stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

22 Jul 22
12 Aug 22
30 Apr 23
Quarter (USD) Apr 22 Jan 22 Oct 21 Jul 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Apr 22 Apr 21 Apr 20 Apr 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 9.01M 9.01M 9.01M 9.01M 9.01M 9.01M
Cash burn (monthly) (no burn) (no burn) 115.33K (no burn) (no burn) (no burn)
Cash used (since last report) n/a n/a 395.8K n/a n/a n/a
Cash remaining n/a n/a 8.61M n/a n/a n/a
Runway (months of cash) n/a n/a 74.7 n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
5 Nov 21 Tobin Scott R Option to purchase Common Stock Common Stock Grant Acquire A No No 10.1 14,851 150K 14,851
5 Nov 21 Philip P. Breitfeld Option to purchase Common Stock Common Stock Grant Acquire A No No 10.1 8,045 81.25K 8,045
5 Nov 21 Ackerman Joel Option to purchase Common Stock Common Stock Grant Acquire A No No 10.1 18,564 187.5K 18,564
5 Nov 21 Sidransky David Option to purchase Common Stock Common Stock Grant Acquire A No No 10.1 8,045 81.25K 8,045
5 Nov 21 Mendelson Daniel Newman Option to purchase Common Stock Common Stock Grant Acquire A No No 10.1 13,614 137.5K 13,614
50.4% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 30 16 +87.5%
Opened positions 16 2 +700.0%
Closed positions 2 22 -90.9%
Increased positions 2 3 -33.3%
Reduced positions 3 3
13F shares Current Prev Q Change
Total value 56.33M 12.84M +338.9%
Total shares 6.82M 1.46M +368.5%
Total puts 0 0
Total calls 224.7K 0 NEW
Total put/call ratio
Largest owners Shares Value Change
Battery Management 2.42M $19.69M NEW
NEA Management 1.71M $13.93M NEW
West Elk Partners 676.94K $6.4M 0.0%
Vanguard 345.84K $2.81M NEW
Millrace Asset 328.98K $2.68M NEW
Tocqueville Asset Management 252.46K $2.05M NEW
Renaissance Technologies 169.94K $1.38M -10.9%
BLK Blackrock 122.8K $999K -0.5%
Essex Investment Management 115.08K $936K +8.1%
Dimensional Fund Advisors 111.92K $910K +1.2%
Largest transactions Shares Bought/sold Change
Battery Management 2.42M +2.42M NEW
NEA Management 1.71M +1.71M NEW
Vanguard 345.84K +345.84K NEW
Millrace Asset 328.98K +328.98K NEW
Tocqueville Asset Management 252.46K +252.46K NEW
AMP Ameriprise Financial 85.05K +85.05K NEW
Overbrook Management 63.89K +63.89K NEW
ClariVest Asset Management 48.2K +48.2K NEW
Aristides Capital 36.75K +36.75K NEW
Susquehanna Fundamental Investments 26.94K +26.94K NEW

Financial report summary

?
Competition
Vyant Bio
Risks
  • We historically incurred losses from operating activities, may require significant capital and may never achieve sustained profitability.
  • We may incur greater costs than anticipated, which could result in sustained losses.
  • We may not be able to implement our business strategies which could impair our ability to continue operations.
  • Our laboratories are subject to regulation and licensure requirements, and the healthcare industry is highly regulated; we may face substantial penalties, and our business activities may be impacted, if we fail to comply.
  • If our laboratory facilities are damaged or destroyed, or we have a dispute with one of our landlords, our business would be negatively affected.
  • Any health crisis impacting our colony of laboratory mice could have a negative impact on our business.
  • We have limited experience marketing and selling our products and may need to rely on third parties to successfully market and sell our products and generate revenues.
  • We will continue to be dependent upon key employees.
  • Because our industry is very competitive and many of our competitors have substantially greater capital resources and more experience in research and development, we may not succeed in selling or increasing sales of our products and technologies.
  • If we are unable to protect our intellectual property, we may not be able to compete as effectively.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • Claims by others that our products infringe their patents or other intellectual property rights could adversely affect our financial condition.
  • Research service studies are subject to cancellation based on changes in customer’s development plans.
  • We face competition in the life science market for computational software and for bioinformatics products.
  • Our ability to use our net operating loss carry-forwards and certain other tax attributes may be limited.
  • We have a limited market for our common stock, which makes our securities very speculative.
  • Investment in our common stock may be diluted if we issue additional shares in the future.
  • Our stock price is volatile and therefore investors may not be able to sell their common stock at or above the price they paid for it.
  • Certain provisions of our charter and bylaws and of our contractual agreements contain provisions that could delay and discourage takeover attempts and any attempts to replace our current management by stockholders.
  • Our management and four significant stockholders collectively own a substantial majority of our common stock.
  • We have not paid any cash dividends in the past and have no plans to issue cash dividends in the future, which could cause the value of our common stock to have a lower value than other similar companies which do pay cash dividends.
  • If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the price of our common stock and trading volume could decline.
  • A pandemic, epidemic, or outbreak of an infectious disease in the United States or elsewhere may adversely affect our business and we are unable to predict the potential impact.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: assest, attempt, automated, bringing, catastrophic, conflict, cyber, cybersecurity, denial, efficiency, energy, expose, feasibility, formalized, fuel, geopolitical, hacking, heightened, ID, interruption, Italy, leakage, left, LEONE, malfeasance, manual, Milan, military, mitigate, monitor, monitored, occupancy, passed, phishing, pose, principal, prolonged, proper, ransomware, Russia, shutdown, storage, store, stored, strength, transmit, turmoil, Ukraine, variety, viability, violation, vulnerable, XIII
Removed: achieved, adjustment, ahead, assume, attribution, book, burden, capitalizing, captured, CCA, classify, clearance, companion, Conclusion, conjunction, conventional, decided, decision, device, directed, disposal, disposed, draft, enforcement, exclude, exempt, exercisable, grantor, improved, inclusive, influence, inherent, intent, legislative, limiting, lowering, managed, manufacturer, mature, meaningful, measurement, measuring, Medicaid, Medicare, modified, nonemployee, notified, phased, prescription, proposed, rare, recent, reform, reimbursement, rejection, requirement, retrospective, scope, shift, taxing, trend